Jonathan Kay to Fibrosis
This is a "connection" page, showing publications Jonathan Kay has written about Fibrosis.
Connection Strength
0.900
-
Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117.
Score: 0.286
-
Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41.
Score: 0.280
-
Kay J. Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol. 2008 Sep; 4(9):445.
Score: 0.075
-
Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug; 58(8):2543-8.
Score: 0.074
-
Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204.
Score: 0.074
-
Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21; 358(8):827-38.
Score: 0.072
-
Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
Score: 0.026
-
Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004 Nov 18; 351(21):2219-27.
Score: 0.014